MS: The New Treatment Paradigm: A Pathway to Success for Improved Patient Outcomes
 A continuing medical education activity sponsored by NAMCP and AAMCN
This activity was held live at the 2008 Fall Managed Care Forum.

This activity is valid from January 5, 2009 to December 31, 2009
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Bayer Healthcare, Inc.
PLEASE CLICK HERE TO VIEW PRESENTATION

 PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU:  View the presentation, answer the post test, complete the evaluation form and submit to keads@namcp.org.  A score of 70% must be achieved on the post test to receive continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or by faxing them to Katie Eads at 804-747-5316.

Summary
With advances in the understanding of the dual nature of multiple sclerosis (MS) – inflammation and nerve fiber destruction, treatment is now recommended in earlier phases of the disease. Early treatment after the first attack of symptoms highly suggestive of MS with disease modifying medications can delay progression to clinically definite MS. Early treatment can also significantly delay the development of disability. Because of the effects on progression and disability, overall cost savings should occur with early treatment.

Objectives

  • Identify the pathophysiology, demographics, current treatment modalities, and management challenges of Multiple Sclerosis

  • Discuss recent clinical studies demonstrating the benefits of early treatment to reduce the progression of MS

  • Discuss evidence based medicine principles identified in clinical literature and used by experts in multiple sclerosis

  • Describe the tolerability and adherence issues related to multiple sclerosis therapy

  • Examine the economic impact of early treatment of MS on managed care plans and plan members

Faculty: Jack Burks, MD, Neurologist, University of Nevada-School of Medicine
   

Disclosure:

 Dr. Burks has disclosed the following:
Speaker Fees:  Bayer, Elan, Serono and Teva Neuroscience
Consultant:   Bayer, BIO MS, Marnac, Pfizer, Serona and Teva Neuroscience.
Dr. Burks use of trade names in this activity is for the learners’ reference only. No promotion of or preference for any product should be inferred.
  The NAMCP planning committee has no real or perceived financial relationships to disclose.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. NAMCP designates this activity for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA) VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1.0 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

  

This activity is supported by an educational grant from Bayer Healthcare, Inc.